Skip to main content

Table 2 Summary of secondary end point analyses

From: IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis

  1. 1Baselinemeasurement refers to the baseline measurement of the variable being analysed
  2. 2Other component scores of AHHS are included in the analysis of dichotomous variables
Back to article page

Trials

ISSN: 1745-6215